GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a small molecule that selectively inhibits NADPH oxidase isoforms Nox1 and Nox4, key generators of pathological reactive oxygen species (ROS) (APExBIO). It demonstrates Ki values of 140 nM (Nox1) and 110 nM (Nox4) in cell-free enzymatic assays, indicating high potency. GKT137831 reduces oxidative stress and modulates downstream signaling pathways including Akt/mTOR and NF-κB, impacting cellular proliferation and fibrosis (Yang et al., 2025). In vivo, oral administration at 30–60 mg/kg/day attenuates pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis in mouse models. The compound is highly soluble in DMSO (≥39.5 mg/mL) but insoluble in water, dictating specific handling requirements. Its selectivity and clinical validation distinguish it as a reference tool in advanced redox biology workflows.

Biological Rationale

NADPH oxidases (Nox enzymes) are primary sources of superoxide and hydrogen peroxide in mammalian cells, driving oxidative stress in diverse pathological contexts (Yang et al., 2025). Nox1 and Nox4 isoforms are implicated in chronic inflammation, fibrosis, vascular remodeling, and metabolic syndromes. Excess ROS triggers deleterious signaling cascades, modulating membrane dynamics, lipid peroxidation, and cell death pathways such as ferroptosis. Targeted inhibition of Nox1/Nox4 allows researchers to dissect redox contributions to disease without broadly suppressing physiological ROS required for immune defense and signaling. GKT137831, developed and distributed by APExBIO, fulfills this role by selectively blocking Nox1/Nox4-derived ROS, offering precise redox modulation in both basic and translational research (product page).

Mechanism of Action of GKT137831

GKT137831 acts as a competitive inhibitor of NADPH oxidase isoforms Nox1 and Nox4, binding their catalytic sites with nanomolar affinity (Ki = 140 nM for Nox1, 110 nM for Nox4). Inhibition prevents electron transfer from NADPH to molecular oxygen, reducing superoxide (O2•−) and subsequent hydrogen peroxide (H2O2) formation. Lowered ROS levels blunt activation of redox-sensitive pathways, notably Akt/mTOR and NF-κB, which regulate cellular proliferation, inflammation, and extracellular matrix deposition. GKT137831 also attenuates TGF-β1 expression and upregulates PPARγ, shifting cellular responses toward anti-fibrotic and anti-inflammatory phenotypes. In relevant cellular models, the compound reduces hypoxia-induced H2O2 release and inhibits proliferation of human pulmonary artery endothelial and smooth muscle cells under pathological conditions. These effects translate to the tissue level, curbing maladaptive remodeling in animal models of chronic hypoxia, fibrosis, and atherosclerosis (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 activity with a Ki of 140 nM and Nox4 activity with a Ki of 110 nM in cell-free systems (APExBIO).
• In vitro, GKT137831 (0.1–20 μM, 24 h, DMSO vehicle) significantly reduces hypoxia-induced H2O2 production in human pulmonary artery endothelial cells (HPAECs) (Yang et al., 2025).
• GKT137831 inhibits proliferation of both HPAECs and human pulmonary artery smooth muscle cells (HPASMCs) under pro-oxidant conditions (Yang et al., 2025).
• Oral dosing at 30–60 mg/kg/day in mouse models attenuates chronic hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy (APExBIO).
• GKT137831 reduces liver fibrosis and diabetes-accelerated atherosclerosis in vivo, with modulation of TGF-β1 and PPARγ expression (Yang et al., 2025).
• Compound is highly soluble in DMSO (≥39.5 mg/mL), moderately soluble in ethanol (≥2.96 mg/mL with warming/sonication), and insoluble in water, which informs workflow design (APExBIO).
• Clinical studies have evaluated GKT137831 for safety and target engagement in human subjects (see product documentation).

This article extends insights from 'GKT137831: Advanced Redox Modulation for Disease Modeling' by detailing quantitative benchmarks and workflow integration protocols not covered in that overview.

Applications, Limits & Misconceptions

GKT137831 is validated as a research tool for dissecting the role of Nox1/Nox4-derived ROS in models of fibrosis, vascular remodeling, metabolic syndrome, and redox-driven signaling. It is not a pan-Nox inhibitor and does not target Nox2 or the entire family. Its selectivity ensures minimal off-target suppression of physiological ROS, facilitating interpretable results in specific disease models. The compound's clinical translation underscores its value in bridging preclinical and human studies.

Common Pitfalls or Misconceptions

• GKT137831 is not effective in models where Nox2 or other non-Nox1/Nox4 isoforms predominate; results may be negative in immune cell–driven ROS responses.
• The compound is insoluble in water; improper solvent use can compromise assay reproducibility and cell viability.
• Long-term storage of GKT137831 solutions at room temperature leads to degradation; always store at −20°C and avoid repeated freeze-thaw cycles.
• Clinical efficacy in humans remains under investigation; preclinical findings may not fully extrapolate to clinical contexts.
• Inhibition of Nox1/Nox4 does not broadly suppress all forms of oxidative stress, especially those driven by mitochondrial or peroxisomal sources.

For a scenario-driven protocol comparison, see 'Optimizing Oxidative Stress Assays'; this article provides updated solvent and workflow guidance not detailed in that source.

For an in-depth exploration of dual Nox1/Nox4 inhibition in translational redox biology, contrast with 'GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress', which emphasizes foundational and troubleshooting contexts. This article focuses on evidence-based parameters and clinical relevance.

Workflow Integration & Parameters

GKT137831 is supplied as a solid by APExBIO (SKU B4763) and should be dissolved in DMSO to create a ≥39.5 mg/mL stock solution. For most cell culture studies, dilute to final concentrations of 0.1–20 μM, ensuring DMSO does not exceed 0.1–0.2% (v/v) in the medium. Incubation times typically span 24 hours but should be tailored to cell type and endpoint. For in vivo work, oral gavage at 30–60 mg/kg/day is standard in mouse models of fibrosis and vascular remodeling. Always store dry powder at −20°C and avoid long-term storage of reconstituted solutions. Analytical verification of compound integrity is recommended before large-scale experiments. Use validated controls to distinguish Nox1/Nox4-specific effects from off-target ROS suppression. Refer to 'Strategic Redox Modulation: GKT137831 and the Translation...' for paradigm-shifting workflow examples; this article further specifies solvent compatibility and clinical translation boundaries.

Conclusion & Outlook

GKT137831 is a reference dual Nox1/Nox4 inhibitor, enabling precise research on oxidative stress, fibrosis, and vascular pathology. Its selectivity, potency, and validated workflow integration make it indispensable for redox biology. Ongoing clinical evaluation will clarify its translational impact. For reagent details and ordering, see the GKT137831 product page at APExBIO.